-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Crosses Below Fifty Day Moving Average of $3.65
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Crosses Below Fifty Day Moving Average of $3.65
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating)'s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares.
ZIVO Bioscience Trading Down 0.3 %
The stock has a market capitalization of $28.45 million, a price-to-earnings ratio of -3.05 and a beta of -0.05. The firm has a 50-day moving average of $3.65 and a 200 day moving average of $3.56.
Get ZIVO Bioscience alerts:ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Insider Activity at ZIVO Bioscience
In other ZIVO Bioscience news, Director Christopher D. Maggiore bought 7,200 shares of the stock in a transaction that occurred on Wednesday, September 14th. The shares were purchased at an average cost of $3.53 per share, for a total transaction of $25,416.00. Following the transaction, the director now directly owns 810,305 shares in the company, valued at $2,860,376.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.10% of the stock is owned by insiders.Hedge Funds Weigh In On ZIVO Bioscience
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. raised its position in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. 5.04% of the stock is owned by institutional investors.
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Featured Articles
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating)'s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares.
Zivo Bioscience，Inc.(場外交易代碼：Zivo-Get Rating)的股價在週二的交易中跌破了50日移動均線。該股的50日移動均線為3.65美元，最低交易價格為2.85美元。Zivo Bioscience的股票最新報3.02美元，成交量為6,150股。
ZIVO Bioscience Trading Down 0.3 %
Zivo生物科學公司股價下跌0.3%
The stock has a market capitalization of $28.45 million, a price-to-earnings ratio of -3.05 and a beta of -0.05. The firm has a 50-day moving average of $3.65 and a 200 day moving average of $3.56.
該股市值為2,845萬美元，市盈率為-3.05，貝塔係數為-0.05。該公司的50日移動均線切入位在3.65美元，200日移動均線切入位在3.56美元。
ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Zivo Bioscience(場外交易市場代碼：Zivo-Get Rating)最近一次公佈財報是在8月4日星期四。這家生物技術公司公佈了本季度每股收益(0.22美元)。
Insider Activity at ZIVO Bioscience
Zivo Bioscience的內部活動
Hedge Funds Weigh In On ZIVO Bioscience
對衝基金參與Zivo Bioscience
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. raised its position in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. 5.04% of the stock is owned by institutional investors.
一家機構投資者最近提高了對Zivo Bioscience股票的頭寸。先鋒集團在最近提交給美國證券交易委員會的13F文件中稱，該公司第一季度將其在Zivo Bioscience，Inc.(場外交易代碼：Zivo-Get)的股票持倉上調了19.6%。該機構投資者在本季度額外購買了15,147股後，持有這家生物技術公司92,468股股票。據先鋒集團最新提交的美國證券交易委員會申報文件顯示，該公司持有Zivo Bioscience約0.98%的股份，價值35.9萬美元。5.04%的股份由機構投資者持有。
About ZIVO Bioscience
關於Zivo生物科學
(Get Rating)
(獲取評級)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience，Inc.是一家研發公司，致力於向動物、人類、膳食補充劑和醫用食品製造商許可和銷售從其專有藻類培養物中提取的天然生物活性成分。它在生物技術和農業技術部門開展業務，擁有知識產權組合，包括專有藻類和細菌菌株、生物活性分子和複合體、生產技術、栽培技術，以及應用於人類和動物健康的專利或正在申請專利的發明。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免費獲取StockNews.com關於Zivo生物科學的研究報告(Zivo)
- 防禦性股票應對動盪的市場
- SunPower準備推動三位數的收益增長
- UPS會成為下一個發出警告的公司嗎？
- 這是Gap Stock黎明前最黑暗的一次嗎？
- 與捷普公司一起打造更好的技術產品組合。
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zivo生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zivo Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧